Prevalence of and Risk Factors for Hyperuricemia in Urban Chinese Check‐Up Population
International Journal of Endocrinology · 2024-01 · 2024 (1)
DOI: 10.1155/2024/8815603 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endocrinology, online erschienen am 30.10.2024. Verfasst von Tianxing Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Affairs, Shanghai Clinical Research and Trial Center, Shanghai 201203, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The prevalence of hyperuricemia is increasing globally. The health check‐up population is a group of people dedicated to disease prevention in public health. This study aims to estimate the current prevalence of hyperuricemia among the health check‐up population in economically developed areas of China using a healthcare database.
Method
Healthcare data from 48,988 subjects in 12 provinces of China who had an annual health check‐up in 2021 were used. Hyperuricemia was defined as a serum urate level > 420 mmol/L and/or a history of physician‐diagnosed gout. An alternative definition of serum urate level > 420 mmol/L in men and > 360 mmol/L in women was used. The stratified prevalence of hyperuricemia by sex, age, region, and comorbidity group was reported. The association between hyperuricemia and sex, age, region, and comorbidities was analyzed in the multivariate logistic regression model.
Results
In 2021, the sex‐ and age‐adjusted prevalence of hyperuricemia was 13.6% in the total population (24.3% in men and 2.6% in women) based on the definition of serum urate level > 420 mmol/L. Regional prevalence varied considerably across the country, with the highest prevalence found in Fujian and the lowest in Liaoning Province (21.6% vs. 7.3%). Male sex, aging, hypertension, obesity, abdominal obesity, hypertriglyceridemia, and hypercholesterolemia were likely to be associated with hyperuricemia.
Conclusions
This is the largest study using a healthcare database to indicate the prevalence of hyperuricemia in a health check‐up population in an economically developed area of China. The current prevalence among the Chinese health check‐up population was substantial, with a higher prevalence in males and in the eastern region. Hyperuricemia and its comorbidities warrant greater attention in the developed areas of China.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Affairs, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.
- Department of Spine Surgery, The First People's Hospital of Nantong, Nantong 226001, Jiangsu, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Center for RNA Therapeutics, Houston Methodist Research Institute, Houston 77030, Texas, USA.
- Business Division of Health Check-Up, Rici Health Care Holdings Limited, Shanghai 200126, China.
- Department of Nephrology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
ORCID-Profile: Tianxing Feng, Chaochen Li, Li Zhao, Jiawei Yu
Zitieren
APA
Feng, T., Li, C., Zheng, J., Xu, Y., Wang, X., Li, Y., Wang, Y., Zhu, B., Zhao, L., & Yu, J. (2024). Prevalence of and Risk Factors for Hyperuricemia in Urban Chinese Check‐Up Population. International Journal of Endocrinology, 2024(1). https://doi.org/10.1155/2024/8815603
Vancouver
Feng T, Li C, Zheng J, Xu Y, Wang X, Li Y, et al. Prevalence of and Risk Factors for Hyperuricemia in Urban Chinese Check‐Up Population. International Journal of Endocrinology. 2024;2024(1). doi:10.1155/2024/8815603
BibTeX
@article{Feng2024,
author = {Feng, Tianxing and Li, Chaochen and Zheng, Jiali and Xu, Yaqing and Wang, Xiaoxiao and Li, Yisen and Wang, Yilei and Zhu, Beili and Zhao, Li and Yu, Jiawei},
title = {Prevalence of and Risk Factors for Hyperuricemia in Urban Chinese Check‐Up Population},
journal = {International Journal of Endocrinology},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/8815603}
}
EUVIMED